Morcellation and Cancer Risk: What Patients Should Know

Morcellation and Cancer: Understanding the Risk

Morcellation is a surgical technique that breaks tissue into small pieces so it can be removed through a small incision, typically during laparoscopic hysterectomy or myomectomy. The concern is straightforward: if the tissue being morcellated contains an unsuspected uterine sarcoma or other malignancy, the procedure can disperse cancer cells throughout the abdomen and pelvis, upstaging the disease and worsening the prognosis.

The U.S. Food and Drug Administration (FDA) has cautioned against the use of laparoscopic power morcellators in the majority of women undergoing hysterectomy or myomectomy for fibroids, estimating that approximately 1 in 350 women with fibroids may have an unsuspected uterine sarcoma. This guidance has reshaped how gynecologic surgeons discuss and plan minimally invasive procedures.

How Morcellation Can Spread Cancer

When a surgeon uses a power morcellator inside the uterus or abdominal cavity, spinning blades fragment the tissue into small strips that are suctioned out or extracted through the narrow trocar site. If a malignant tumor is present, this process can spray cancerous cells onto the peritoneal surfaces, the bowel, the bladder, and the abdominal wall. What was once an early-stage, potentially curable cancer can become stage IV disseminated disease that is far harder to treat.

The risk is not limited to the procedure itself. Even containment strategies, if not executed perfectly, can leave behind microscopic fragments that may implant and grow. This is why informed consent before surgery now routinely includes a discussion about morcellation and its potential consequences.

Which Cancers Are Involved

The primary cancer of concern is uterine leiomyosarcoma, an aggressive tumor of the uterine muscle wall. It is difficult to diagnose preoperatively because it can mimic benign fibroids on imaging and biopsy. Endometrial stromal sarcoma and other rare uterine malignancies are also considerations. In some cases, non-gynecologic cancers that have spread to the uterus or ovaries may be present in tissue that is morcellated.

FDA Warnings and Regulatory History

The FDA first issued a safety communication about power morcellators in 2014, followed by a more definitive recommendation that these devices should not be used for most women undergoing hysterectomy or myomectomy. The agency classified the concern around unsuspected sarcoma as a serious risk that outweighed the benefits of minimally invasive removal through small incisions. This led many manufacturers to add contraindications to their labeling and prompted hospitals across the country to review their morcellation practices.

Containment Techniques and Their Limits

In response to the FDA warnings, surgeons developed containment methods. The most common involves placing the tissue inside a specialized bag before morcellation, theoretically trapping any malignant cells inside the bag during extraction. While containment bags reduce the risk of surface dissemination, they do not eliminate it. Tissue fragments can escape through small tears in the bag, or the bag itself may be difficult to deploy in all anatomical situations. Surgeons and patients should understand that containment is a risk-reduction strategy, not a risk-elimination strategy.

Alternatives to Morcellation

Surgeons have several options for removing the uterus or fibroids without morcellation. The tissue can be cut into larger strips and removed through a slightly larger incision, a technique called manual morcellation or enucleation. Vaginal removal of the uterus avoids abdominal morcellation altogether. For some patients, an open abdominal surgery provides the safest route for tissue extraction when cancer cannot be ruled out preoperatively.

Questions to Ask Your Surgeon

Patients facing gynecologic surgery should have a clear conversation with their surgeon before the procedure. Key questions include:

• Is morcellation planned, and what type of morcellator will be used?
• What is the preoperative assessment of my risk for uterine cancer?
• Will a containment bag be used if morcellation proceeds?
• What is the plan if cancer is discovered during surgery?
• Are there alternatives that avoid morcellation entirely for my specific condition?

When Morcellation May Still Be Appropriate

Morcellation is not universally contraindicated. In cases where the tissue has been thoroughly evaluated and the likelihood of malignancy is extremely low, some surgeons may still recommend power morcellation for its minimally invasive benefits. The decision depends on the patient's age, symptoms, imaging findings, menopausal status, and personal risk factors. A shared decision-making process that weighs the benefits of a smaller incision and faster recovery against the small but real risk of cancer dissemination is essential.

Conclusion

Morcellation remains a valuable surgical tool, but its use requires careful patient selection and full transparency about the cancer risk. Preoperative counseling, informed consent, and a clear plan for tissue extraction can help ensure that patients are protected from the unintended consequences of spreading an undiagnosed malignancy during surgery.